CureVac N.V. (CVAC)

CureVac N.V. is a biotechnology company founded in 2000 by Ingmar Hoerr in Tübingen, Germany. It focuses on developing transformative medicines based on messenger RNA (mRNA) technology. The company gained significant attention for its innovative mRNA-based vaccine approach, especially during the COVID-19 pandemic. CureVac is committed to leveraging its extensive expertise in RNA optimization and delivery to create vaccines, cancer therapies, and treatments for rare diseases. As a publicly traded company, CureVac was listed on the Nasdaq under the symbol CVAC in August 2020. The company continues to focus on research and development, with strategic collaborations aimed at advancing its mRNA technology platform.